imipramine has been researched along with verapamil in 127 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (9.45) | 18.7374 |
| 1990's | 11 (8.66) | 18.2507 |
| 2000's | 33 (25.98) | 29.6817 |
| 2010's | 66 (51.97) | 24.3611 |
| 2020's | 5 (3.94) | 2.80 |
| Authors | Studies |
|---|---|
| Creveling, CR; Daly, JW; Lewandowski, GA; McNeal, ET | 1 |
| Gubernator, K; Kansy, M; Senner, F | 1 |
| Conway, SJ; Ganapathy, V; George, RL; Huang, W; Leibach, FH; Wang, H; Wu, X | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
| Cavalli, A; De Ponti, F; Poluzzi, E; Recanatini, M | 1 |
| Keserü, GM | 1 |
| Faassen, F; Spanings, H; Vogel, G; Vromans, H | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Bacsó, Z; Cianfriglia, M; Fenyvesi, F; Goda, K; Kappelmayer, J; Lustyik, G; Nagy, H; Szabó, G; Szilasi, M | 1 |
| Johans, C; Kinnunen, PK; Söderlund, T; Suomalainen, P | 1 |
| Li, J; Rajamani, R; Reynolds, CH; Tounge, BA | 1 |
| Caron, G; Ermondi, G | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Bondebjerg, J; Fuglsang, H; Naerum, L; Pedersen, J; Valeur, KR | 1 |
| Akamatsu, M; Fujikawa, M; Nakao, K; Shimizu, R | 1 |
| Abraham, MH; Acree, WE; Ibrahim, A | 1 |
| Cooper, RA; Dodean, RA; Hinrichs, DJ; Janowsky, A; Johnson, RA; Kelly, JX; Lane, KD; Riscoe, M; Smilkstein, MJ; Winter, R | 1 |
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Jia, L; Sun, H | 1 |
| He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Sun, Y; Yan, Z | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Caron, G; Ermondi, G; Visentin, S | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Andrisano, V; Barril, X; Bartolini, M; Carreiras, Mdo C; de los Ríos, C; García, AG; Huertas, O; León, R; López, B; López, MG; Luque, FJ; Marco-Contelles, J; Rodríguez-Franco, MI; Samadi, A; Villarroya, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Andrisano, V; Arce, MP; Badia, A; Bartolini, M; Camps, P; Clos, MV; Dafni, T; Formosa, X; Galdeano, C; Gómez, E; Huertas, O; Isambert, N; Lavilla, R; Luque, FJ; Mancini, F; Muñoz-Torrero, D; Ramírez, L; Rodríguez-Franco, MI | 1 |
| Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
| Arce, MP; Conde, S; García, AG; González-Muñoz, GC; López, B; López, MG; Pérez, C; Rodríguez-Franco, MI; Villarroya, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Gozalbes, R; Pineda-Lucena, A | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Akamatsu, M | 1 |
| Claxton, CR; Curran, RE; Harradine, PJ; Hutchison, L; Littlewood, P; Martin, IJ | 1 |
| Sen, S; Sinha, N | 1 |
| Cooper, J; Cui, Y; Fink, M; Gavaghan, DJ; Heath, BM; McMahon, NC; Mirams, GR; Noble, D; Sher, A | 1 |
| Arce, MP; Conde, S; del Barrio, L; Egea, J; García, AG; González-Muñoz, GC; León, R; López, B; López, MG; Martín-de-Saavedra, MD; Pérez, C; Rodríguez-Franco, MI; Romero, A; Villarroya, M | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Caradonna, NP; Hallifax, D; Houston, JB; Turlizzi, E; Zanelli, U | 1 |
| Barber, S; Dew, TP; Farrell, TL; Poquet, L; Williamson, G | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
| Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
| Peters, JU | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Andrisano, V; Bartolini, M; Clos, MV; Di Pietro, O; Juárez-Jiménez, J; Lavilla, R; Luque, FJ; Muñoz-Torrero, D; Pérez, B; Ramón, R; Viayna, E; Vicente-García, E | 1 |
| Artursson, P; Mateus, A; Matsson, P | 1 |
| Clos, MV; Di Pietro, O; Espargaró, A; Juárez-Jiménez, J; Lavilla, R; Luque, FJ; Muñoz-Torrero, D; Pérez, B; Pérez-Areales, FJ; Sabaté, R | 1 |
| Clos, MV; Di Pietro, O; Espargaró, A; Galdeano, C; Guillou, C; Lamuela-Raventós, RM; Luque, FJ; Muñoz-Torrero, D; Pérez, B; Pérez-Areales, FJ; Ragusa, IM; Sabaté, R; Vallverdú-Queralt, A; Viayna, E | 1 |
| Artigas, A; Clos, MV; Gbedema, SY; Kelly, JM; Muñoz-Torrero, D; Pérez, B; Sola, I; Taylor, MC; Wright, CW | 1 |
| Deng, Y; Li, Y; Liu, Q; Qiang, X; Sang, Z; Tan, Z; Xiao, G | 1 |
| Berenguer, D; Clos, MV; Di Pietro, O; Fisa, R; Kelly, JM; Lanzoni, A; Lavilla, R; Muñoz-Torrero, D; Pérez, B; Riera, C; Sayago, H; Sola, I; Taylor, MC; Viayna, E; Vicente-García, E | 1 |
| Caflisch, A; Dong, J; Kolb, P; Lafleur, K; Liebl, J; Nevado, C; Unzue, A; Zahler, S; Zhao, H; Zhou, T | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Deng, Y; Li, Y; Luo, L; Qiang, X; Tan, Z; Xiao, G | 1 |
| Alam, MA; Drewes, LR; Gurrapu, S; Jonnalagadda, SK; Lueth, EA; Mereddy, VR; Nelson, GL; Ronayne, CT; Solano, LN | 1 |
| Alencar, N; Di Pietro, O; Esteban, G; Juárez-Jiménez, J; Luque, FJ; Muñoz-Torrero, D; Pérez, B; Sola, I; Solé, M; Szałaj, N; Unzeta, M; Vázquez, J; Viayna, E | 1 |
| Artigas, A; Clos, MV; Kelly, JM; Muñoz-Torrero, D; Pérez, B; Pérez-Areales, FJ; Sola, I; Taylor, MC; Viayna, E; Wright, CW | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Sang, Z; Su, F; Xiao, G; Yang, X; Zheng, Y | 1 |
| Ai, J; Deng, Y; Li, Y; Liu, Q; Luo, L; Qiang, X; Tan, Z; Xiao, G; Yang, X | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Sang, Z; Su, F; Xiao, G; Xu, R; Yang, X; Zheng, Y | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Tan, Z; Xu, R; Yang, X; Zheng, Y | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Song, Q; Tan, Z; Xiao, G; Xu, R; Yang, X | 1 |
| Arce, MP; Conde, S; Egea, J; Gil, C; León, R; López, MG; Monjas, L; Pérez, C; Rodríguez-Franco, MI; Villarroya, M | 1 |
| Bai, P; Leng, C; Li, X; Liu, W; Ma, Q; Pan, W; Sang, Z; Tan, Z; Wang, K; Xu, Q; Yang, Y; Yu, L | 1 |
| Liu, W; Ma, Q; Pan, W; Sang, Z; Wang, K; Yu, L | 1 |
| Han, X; Liu, W; Ma, Q; Sang, Z; Wang, H; Wang, K; Ye, M; Yu, L | 2 |
| Huang, Q; Jiang, N; Li, Q; Liang, N; Liu, J; Xie, SS | 1 |
| Cao, Z; Deng, Y; Li, Y; Liu, H; Qiang, X; Song, Q; Tan, Z; Xu, R; Yang, J; Zhang, X | 1 |
| Handzlik, J; Jastrzębska-Więsek, M; Kieć-Kononowicz, K; Kucwaj-Brysz, K; Latacz, G; Lubelska, A; Partyka, A; Wesołowska, A | 1 |
| Abouf, M; Abutaleb, NS; Chen, L; Elsebaei, MM; Ghiaty, A; Hegazy, YA; Malwal, SR; Mayhoub, AS; Mohammad, H; Oldfield, E; Seleem, MN; Zhang, J | 1 |
| Deng, Y; Li, Y; Liu, H; Song, Q; Tan, Z; Xiao, G; Xu, R; Yang, Z; Zhang, X; Zheng, Y | 1 |
| An, Q; Deng, Y; Liu, P; Luo, Y; Sang, Z; Tang, Y; Wang, T; Yang, T; Yang, Y; Zhang, T | 1 |
| Alcaro, S; Bagetta, D; Borges, F; Cagide, F; Oliveira, PJ; Ortuso, F; Pérez, C; Reis, J; Rodríguez-Franco, MI; Teixeira, J; Uriarte, E; Valencia, ME | 1 |
| Cao, Z; Deng, Y; Li, Y; Liu, H; Qiang, X; Song, Q; Tan, Z; Tian, C; Yang, Z | 1 |
| Deng, Y; He, Y; Li, W; Liu, H; Qiang, X; Song, Q; Tan, Z; Ye, C | 1 |
| Liu, W; Sang, Z; Shi, J; Tan, Z; Wang, K | 1 |
| Liu, W; Sang, Z; Shi, J; Tan, Z; Wang, K; Zhang, P | 1 |
| Andrisano, V; Barniol-Xicota, M; Bartolini, M; De Simone, A; Espargaró, A; Muñoz-Torrero, D; Pérez, B; Pérez-Areales, FJ; Pivetta, D; Pont, C; Sabate, R; Sureda, FX; Turcu, AL; Vázquez, S | 1 |
| Fan, X; Liu, W; Sang, Z; Shi, J; Wang, K; Yang, D; Zhang, P; Zhang, Z; Zhu, G | 1 |
| Bai, P; Cheng, X; Cheng, Y; Lu, X; Sang, Z; Shi, J; Wang, K; Yang, J; Zhang, P; Zhang, Q; Zheng, C | 1 |
| Guo, HF; Jin, J; Li, ZR; Liu, ZY; Xie, ZS; Xue, ST; Yi, H; Zhang, L | 1 |
| Abutaleb, NS; Alhashimi, M; Kassab, AE; Mayhoub, AS; Mohamed, KO; Seleem, MN; Shahin, IG; Taher, AT | 1 |
| Acevedo, O; Dasararaju, G; Devadasan, V; Halakova, D; Jayaprakash, V; Kovacikova, L; Mohd Siddique, MU; Mondal, SK; Prnova, MS; Shilkar, D; Stefek, M; Thakur, A; Yasmin, S | 1 |
| Brea, JM; Companys-Alemany, J; Griñán-Ferré, C; Johnson, JW; Kurnikova, MG; Loza, MI; Pallàs, M; Patel, DS; Pérez, B; Phillips, MB; Soto, D; Sureda, FX; Turcu, AL; Vázquez, S | 1 |
| Burchell, A; Scott, HM | 1 |
| Andreeva, NI; Golovina, SM; Mashkovskiĭ, MD; Rumiantsev, EA | 1 |
| Bílá, V; Kren, V | 1 |
| Danis, M; Dukes, GE; Hak, LJ; Han, YH; Hermann, DJ; Hussey, EK; Krol, TF; Powell, JR | 1 |
| Mustafa, AA | 1 |
| Dupont, AG; Huyghens, L; Reynaert, H; Schoors, DF; Vanhaelst, L | 1 |
| Hirai, H; Natori, S; Sekimizu, K | 1 |
| Cohen, A; Eldar, M; Rehavi, M; Weizman, A | 1 |
| Auclair, MC; Lechat, P; Vernimmen, C | 1 |
| Enyeart, JJ; Hinkle, PM; Phillips, WJ | 1 |
| Dunn, J; Fanburg, BL; Lee, SL; Yu, FS | 1 |
| Carmi, R; Rehavi, M; Weizman, A | 1 |
| Geoffroy, M; Mogilnicka, E; Nielsen, M; Rafaelsen, OJ | 1 |
| Dill, PL; Duarte, TE; Nagourney, RA; Su, YZ; Weisenthal, LM | 1 |
| Pollack, MH; Rosenbaum, JF | 1 |
| Filias, N; Jornod, J | 1 |
| Bittar, EE; Nwoga, J | 1 |
| Chiba, S; Furukawa, Y; Watanabe, H | 1 |
| Minakuchi, R; Mori, T; Nishizuka, Y; Takai, Y; Yu, B | 1 |
| Beitlová, D; Bures, P; Fisar, Z; Fuksová, K; Krulík, R; Sikora, J | 1 |
| Ellis, D; Flatman, PW; Gow, IF; Handy, RD | 1 |
| Chiba, S; Furukawa, Y; Hirose, M; Kurogouchi, F; Nakajima, K; Tsuboi, M; Zhao, D | 1 |
| Axelsson, H; Floby, E; Granhall, C; Jaksch, Y; Sohlenius-Sternbeck, AK; Svedling, M | 1 |
| Becker, B; Lebrun, P; Morel, N; Vanbellinghen, AM | 1 |
| Clarke, G; Cryan, JF; Dinan, TG; O'Mahony, SM | 1 |
| Ohkawa, T; Tanaka, Y; Yasui, H | 1 |
| Knegt, L; Koster, EH; Ooms, JA | 1 |
| Furutani, K; Inanobe, A; Kurachi, Y; Ohno, Y; Yamakawa, Y | 1 |
| Clarke, G; Cryan, JF; Dinan, TG; Fitzgerald, P; Griffin, BT; O'Brien, FE | 1 |
| Amad, M; Batonga, J; Bethell, RC; Bolger, G; Cordingley, MG; Duan, J; Garneau, M; Jutras, M; Kukolj, G; Lapeyre, N; Montpetit, H; Otis, F; Rhéaume, M; White, PW | 1 |
| Beeram, S; Bi, C; Hage, DS; Zheng, X | 1 |
| Perry, MS; Turner, AL | 1 |
| Guo, D; Guo, J; Huang, S; Li, Q; Polli, JE; Shu, Y; Xiong, Z; Ye, Z; Zhang, W; Zhou, H; Zhu, P | 1 |
| Gilmore, IS; Hanley, L; Pieterse, CL; Rungger, I; Wickramasinghe, RC | 1 |
4 review(s) available for imipramine and verapamil
| Article | Year |
|---|---|
Polypharmacology - foe or friend?
Topics: Animals; Communicable Diseases; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Polypharmacology; Safety | 2013 |
Three stories on Eph kinase inhibitors: From in silico discovery to in vivo validation.
Topics: Animals; Computer Simulation; Drug Design; Humans; Isoquinolines; Neoplasms; Protein Kinase Inhibitors; Quinoxalines; Receptor, EphB2; Structure-Activity Relationship; Xanthine | 2016 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Outside the box: Medications worth considering when traditional antiepileptic drugs have failed.
Topics: Amantadine; Anticonvulsants; Bumetanide; Central Nervous System Stimulants; Epilepsy; Humans; Imipramine; Lidocaine; Treatment Failure; Verapamil | 2017 |
1 trial(s) available for imipramine and verapamil
| Article | Year |
|---|---|
Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine.
Topics: Administration, Oral; Adolescent; Adult; Antidepressive Agents, Tricyclic; Biological Availability; Desipramine; Diltiazem; Drug Administration Schedule; Drug Interactions; Humans; Imipramine; Labetalol; Male; Verapamil | 1992 |
122 other study(ies) available for imipramine and verapamil
| Article | Year |
|---|---|
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anesthetics, Local; Animals; Batrachotoxins; Calcium Channel Blockers; Cyclic AMP; Guinea Pigs; Histamine H1 Antagonists; In Vitro Techniques; Ion Channels; Neurotoxins; Sodium; Tranquilizing Agents; Tritium | 1985 |
Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.
Topics: Absorption; Adsorption; Caco-2 Cells; Drug Evaluation, Preclinical; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Membranes, Artificial; Permeability; Pharmacokinetics; Spectrophotometry, Ultraviolet | 1998 |
Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta.
Topics: Amino Acid Sequence; Animals; Base Sequence; Carnitine; Carrier Proteins; Cloning, Molecular; DNA, Complementary; Humans; Membrane Proteins; Membrane Transport Proteins; Molecular Sequence Data; Organic Cation Transport Proteins; Placenta; Rats; RNA, Messenger; Solute Carrier Proteins; Structure-Activity Relationship; Symporters; Tetraethylammonium; Tissue Distribution | 2000 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go-Go Potassium Channels; Long QT Syndrome; Models, Molecular; Molecular Conformation; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2002 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain; Caco-2 Cells; Cell Membrane Permeability; Heterocyclic Compounds; Humans; Protein Transport | 2003 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.
Topics: Adenosine Triphosphatases; Animals; Anti-Bacterial Agents; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding, Competitive; Calcium Channel Blockers; Cyclosporine; Detergents; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluoresceins; Humans; Ivermectin; Mice; NIH 3T3 Cells; Substrate Specificity | 2004 |
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
Topics: Blood-Brain Barrier; Lipid Bilayers; Micelles; Permeability; Pharmaceutical Preparations; Structure-Activity Relationship; Surface Properties | 2004 |
A two-state homology model of the hERG K+ channel: application to ligand binding.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Ligands; Models, Biological; Models, Molecular; Potassium Channels, Voltage-Gated; Protein Binding; Protein Conformation | 2005 |
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
Topics: 1-Octanol; Alkanes; Hydrogen-Ion Concentration; Least-Squares Analysis; Mathematics; Models, Chemical; Models, Molecular; Solvents; Water | 2005 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Dipeptidyl nitriles as human dipeptidyl peptidase I inhibitors.
Topics: Cathepsin C; Dipeptides; Enzyme Inhibitors; Humans; Molecular Structure; Nitriles; Stereoisomerism; Structure-Activity Relationship | 2006 |
QSAR study on permeability of hydrophobic compounds with artificial membranes.
Topics: Biological Transport; Caco-2 Cells; Drug Evaluation, Preclinical; Humans; Hydrophobic and Hydrophilic Interactions; Membranes, Artificial; Permeability; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship | 2007 |
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
Topics: Air; Animals; Humans; Lung; Organic Chemicals; Probability; Rats; Tissue Distribution; Volatilization | 2008 |
Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum.
Topics: Acridones; Animals; Antimalarials; Cell Survival; Cells, Cultured; Drug Design; Drug Interactions; Drug Resistance, Multiple; Lymphocytes; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Molecular Structure; Mutation; Parasitic Sensitivity Tests; Plasmodium falciparum; Protozoan Proteins; Structure-Activity Relationship | 2007 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
Topics: Computational Biology; Drug Discovery; Hepatocytes; Humans; Hydrogen-Ion Concentration; Liver; Metabolic Clearance Rate; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship; Sensitivity and Specificity; Software | 2009 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
Topics: Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Potassium Channel Blockers; Quantitative Structure-Activity Relationship | 2009 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Blood-Brain Barrier; Butyrylcholinesterase; Calcium; Calcium Channel Blockers; Catalytic Domain; Cell Death; Cell Line, Tumor; Cholinesterase Inhibitors; Cytosol; Dihydropyridines; Humans; Hydrogen Peroxide; Kinetics; Ligands; Models, Molecular; Peptide Fragments; Permeability; Tacrine | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Binding Sites; Blood-Brain Barrier; Butyrylcholinesterase; Cattle; Cholinesterase Inhibitors; Drug Design; Humans; Isomerism; Membranes, Artificial; Mice; Models, Molecular; Molecular Conformation; Permeability; Protein Binding; Tacrine | 2009 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Catalytic Domain; Cattle; Cell Death; Cell Line, Tumor; Cell Survival; Cholinergic Agents; Cholinesterase Inhibitors; Esters; Glutamic Acid; Humans; Hydrophobic and Hydrophilic Interactions; Neuroprotective Agents; Permeability; Piperidines; Protein Binding | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
QSAR-based solubility model for drug-like compounds.
Topics: Databases, Factual; Models, Molecular; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Solubility; Water | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Importance of physicochemical properties for the design of new pesticides.
Topics: Anabasine; Animals; Biological Availability; Cell Membrane Permeability; Chemical Phenomena; Drug Design; Humans; Imidazoles; Insecticides; Neonicotinoids; Nitro Compounds; Pesticides; Quantitative Structure-Activity Relationship; Receptors, Nicotinic | 2011 |
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
Topics: Animals; Blood Proteins; Buffers; Carbon Dioxide; Chemical Phenomena; Dialysis; Dogs; Drug Evaluation, Preclinical; Humans; Hydrogen-Ion Concentration; Macaca fascicularis; Mice; Osmolar Concentration; Pharmaceutical Preparations; Protein Binding; Rats; Reproducibility of Results | 2011 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
Topics: Action Potentials; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Computer Simulation; Dogs; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Guinea Pigs; HEK293 Cells; Humans; Ion Channels; Kinetics; Models, Cardiovascular; NAV1.5 Voltage-Gated Sodium Channel; Patch-Clamp Techniques; Potassium Channel Blockers; Rabbits; Risk Assessment; Risk Factors; Sodium Channel Blockers; Sodium Channels; Torsades de Pointes; Transfection | 2011 |
N-acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antineoplastic Agents; Butyrylcholinesterase; Calcium; Cell Death; Cell Survival; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Molecular Structure; Okadaic Acid; Peptide Fragments; Phenothiazines; Stereoisomerism; Structure-Activity Relationship; Tumor Cells, Cultured | 2011 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
Topics: Glutathione; Pharmacology; Sulfur Radioisotopes | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
Topics: Cell Line, Tumor; Cryopreservation; Female; Hepatocytes; Humans; Male; Metabolic Clearance Rate; Pharmaceutical Preparations; Predictive Value of Tests | 2012 |
Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
Topics: Artificial Intelligence; Caco-2 Cells; Cell Membrane Permeability; Cinnamates; Enterocytes; Humans; Hydrophobic and Hydrophilic Interactions; Intestinal Absorption; Kinetics; Models, Biological; Molecular Conformation; Osmolar Concentration; Phenols | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
1,2,3,4-Tetrahydrobenzo[h][1,6]naphthyridines as a new family of potent peripheral-to-midgorge-site inhibitors of acetylcholinesterase: synthesis, pharmacological evaluation and mechanistic studies.
Topics: Acetylcholinesterase; Animals; Binding Sites; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Drug Design; Electrophorus; Humans; Membranes, Artificial; Models, Biological; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Naphthyridines; Permeability; Protein Binding | 2014 |
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
Topics: Animals; Brain; Dialysis; HEK293 Cells; High-Throughput Screening Assays; Humans; Pharmaceutical Preparations; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting β-amyloid, tau, and cholinesterase pathologies.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Cholinesterases; Dose-Response Relationship, Drug; Humans; Models, Molecular; Molecular Structure; Naphthyridines; Structure-Activity Relationship; Tacrine; tau Proteins; Tauopathies | 2014 |
Shogaol-huprine hybrids: dual antioxidant and anticholinesterase agents with β-amyloid and tau anti-aggregating properties.
Topics: Acetylcholinesterase; Aminoquinolines; Amyloid beta-Peptides; Antioxidants; Catechols; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Heterocyclic Compounds, 4 or More Rings; Humans; Molecular Structure; Protein Aggregates; Protein Aggregation, Pathological; Structure-Activity Relationship; tau Proteins | 2014 |
Synthesis and antiprotozoal activity of oligomethylene- and p-phenylene-bis(methylene)-linked bis(+)-huprines.
Topics: Antimalarials; Antiprotozoal Agents; Humans; Molecular Structure; Structure-Activity Relationship | 2014 |
Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Apigenin; Blood-Brain Barrier; Butyrylcholinesterase; Carbamates; Cell Line; Chelating Agents; Cholinesterase Inhibitors; Cognition; Glucuronates; Humans; Mice; Molecular Docking Simulation; Neuroprotective Agents; Rats | 2015 |
Multicomponent reaction-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity.
Topics: Acetylcholinesterase; Animals; Antiprotozoal Agents; Cell Line; Cell Survival; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Electrophorus; Leishmania infantum; Molecular Structure; Parasitic Sensitivity Tests; Quinolines; Rats; Structure-Activity Relationship; Trypanosoma brucei brucei; Trypanosoma cruzi | 2015 |
Synthesis and evaluation of 4-hydroxyl aurone derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Benzofurans; Blood-Brain Barrier; Chelating Agents; Copper; Humans; Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Peptide Fragments; Protein Aggregates; Swine | 2016 |
Coumarin carboxylic acids as monocarboxylate transporter 1 inhibitors: In vitro and in vivo studies as potential anticancer agents.
Topics: Animals; Antineoplastic Agents; Carboxylic Acids; Cell Line, Tumor; Cell Proliferation; Coumarins; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Mammary Neoplasms, Experimental; Mice; Molecular Structure; Monocarboxylic Acid Transporters; Structure-Activity Relationship; Symporters | 2016 |
Design, synthesis and biological evaluation of N-methyl-N-[(1,2,3-triazol-4-yl)alkyl]propargylamines as novel monoamine oxidase B inhibitors.
Topics: Dose-Response Relationship, Drug; Drug Design; Humans; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Structure-Activity Relationship | 2016 |
Synthesis and biological evaluation of N-cyanoalkyl-, N-aminoalkyl-, and N-guanidinoalkyl-substituted 4-aminoquinoline derivatives as potent, selective, brain permeable antitrypanosomal agents.
Topics: Aminoquinolines; Brain; Dose-Response Relationship, Drug; Molecular Structure; Parasitic Sensitivity Tests; Structure-Activity Relationship; Trypanocidal Agents; Trypanosoma brucei brucei | 2016 |
Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Isoflavones; Mannich Bases; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship | 2017 |
Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; Drug Design; Electrophorus; Humans; Mannich Bases; Neuroprotective Agents; PC12 Cells; Rats | 2017 |
Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Chalcones; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Rivastigmine; Structure-Activity Relationship; Swine | 2017 |
DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Antipyrine; Benzofurans; Binding Sites; Blood-Brain Barrier; Edaravone; Humans; Hydrogen Bonding; Inhibitory Concentration 50; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Protein Binding; Protein Structure, Tertiary | 2017 |
Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Cell Line; Cholinesterase Inhibitors; Humans; Kinetics; Models, Molecular; Monoamine Oxidase Inhibitors; Thioxanthenes; Xanthones | 2017 |
Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia.
Topics: Alzheimer Disease; Animals; Brain Ischemia; Calcium Channel Blockers; Cholinesterase Inhibitors; Donepezil; Glutamates; Hippocampus; Humans; Indans; Neuroprotective Agents; Piperidines; Rats; Solid-Phase Synthesis Techniques | 2017 |
Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Coumaric Acids; Drug Design; Eels; Humans; Memory Disorders; Mice; PC12 Cells; Rats | 2017 |
Design, synthesis and biological evaluation of 3,4-dihydro-2(1H)-quinoline-O-alkylamine derivatives as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Drug Design; Electrophorus; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quinolines; Swine | 2017 |
Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amines; Binding Sites; Blood-Brain Barrier; Cell Line, Tumor; Cell Survival; Cholinesterase Inhibitors; Cholinesterases; Drug Design; Humans; Inhibitory Concentration 50; Kinetics; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Phthalimides; Protein Structure, Tertiary; Structure-Activity Relationship | 2017 |
Design, synthesis and biological evaluation of 2-acetyl-5-O-(amino-alkyl)phenol derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Benzophenones; Binding Sites; Blood-Brain Barrier; Cell Survival; Cholinesterase Inhibitors; Drug Design; Humans; Hydrogen Peroxide; Inhibitory Concentration 50; Molecular Docking Simulation; Monoamine Oxidase; Neuroprotective Agents; PC12 Cells; Permeability; Phenols; Piperazines; Protein Structure, Tertiary; Rats; Structure-Activity Relationship | 2017 |
Design, synthesis and biological evaluation of new coumarin-dithiocarbamate hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cell Line, Tumor; Cholinesterase Inhibitors; Coumarins; Dose-Response Relationship, Drug; Drug Design; Humans; Kinetics; Male; Mice; Mice, Inbred Strains; Models, Molecular; Molecular Structure; Peptide Fragments; Protein Aggregates; Range of Motion, Articular; Structure-Activity Relationship; Thiocarbamates | 2018 |
Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Line; Cell Survival; Chalcones; Chelating Agents; Copper; Drug Design; Flurbiprofen; Humans; Lipopolysaccharides; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nitric Oxide; Peptide Fragments; Recombinant Proteins; Structure-Activity Relationship | 2018 |
MF-8, a novel promising arylpiperazine-hydantoin based 5-HT
Topics: Dose-Response Relationship, Drug; Humans; Hydantoins; Molecular Structure; Piperazines; Receptors, Serotonin; Serotonin Antagonists; Structure-Activity Relationship | 2018 |
Alkynyl-containing phenylthiazoles: Systemically active antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA).
Topics: Alkynes; Animals; Anti-Bacterial Agents; Half-Life; Methicillin-Resistant Staphylococcus aureus; Mice; Microsomes, Liver; Staphylococcal Infections; Thiazoles | 2018 |
Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Benzylamines; Blood-Brain Barrier; Cholinesterase Inhibitors; Drug Design; Humans; Kinetics; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Permeability; Protein Aggregates; Recombinant Proteins; Structure-Activity Relationship; Thiazoles | 2018 |
Discovery of novel anti-tuberculosis agents with pyrrolo[1,2-a]quinoxaline-based scaffold.
Topics: Antineoplastic Agents; Antitubercular Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Pyrroles; Quinoxalines; Structure-Activity Relationship | 2018 |
Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
Topics: Alzheimer Disease; Blood-Brain Barrier; Cholinesterase Inhibitors; Cholinesterases; Chromones; Drug Design; Hep G2 Cells; Humans; Ligands; Molecular Docking Simulation; Molecular Targeted Therapy; Monoamine Oxidase; Monoamine Oxidase Inhibitors | 2018 |
Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Butyrylcholinesterase; Chelating Agents; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Discovery; Humans; Models, Molecular; Molecular Structure; Peptide Fragments; Phthalimides; Protein Aggregates; Structure-Activity Relationship | 2018 |
Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Cell Line; Cholinesterase Inhibitors; Drug Design; Drug Discovery; Electrophorus; Flurbiprofen; Humans; Mannich Bases; Molecular Docking Simulation; Peptide Fragments; Protein Aggregates; Rats; Swine | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Chalcones; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Eels; Female; Horses; Humans; Male; Maze Learning; Mice; Mice, Inbred Strains; Models, Molecular; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Peptide Fragments; Protein Aggregates; Rats; Structure-Activity Relationship | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Chalcone; Cholinesterase Inhibitors; Drug Design; Eels; Horses; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Peptide Fragments; Protein Aggregates | 2019 |
A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors.
Topics: Acetylcholinesterase; Adamantane; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Molecular Structure; Neuroprotective Agents; Receptors, N-Methyl-D-Aspartate; Structure-Activity Relationship; Tacrine | 2019 |
The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cholinesterases; Donepezil; Drug Design; Drug Development; Humans; Kinetics; Models, Molecular; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship | 2019 |
Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Biological Transport; Blood-Brain Barrier; Butyrylcholinesterase; Chalcones; Chelating Agents; Cholinesterase Inhibitors; Coordination Complexes; Copper; Drug Design; Female; Humans; Male; Memory Disorders; Mice; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Protein Binding; Scopolamine; Structure-Activity Relationship | 2019 |
Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties.
Topics: Animals; Benzofurans; Bone Morphogenetic Protein 2; Caco-2 Cells; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Mice; Mice, Inbred BALB C; Molecular Structure; Osteoporosis; Ovariectomy; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Thiophenes; Zebrafish | 2020 |
Evaluation of N-phenyl-2-aminothiazoles for treatment of multi-drug resistant and intracellular Staphylococcus aureus infections.
Topics: Animals; Anti-Bacterial Agents; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Humans; Methicillin-Resistant Staphylococcus aureus; Mice; Microbial Sensitivity Tests; Microsomes, Liver; Molecular Structure; Staphylococcal Infections; Structure-Activity Relationship; Thiazoles | 2020 |
Non-carboxylic acid inhibitors of aldose reductase based on N-substituted thiazolidinedione derivatives.
Topics: Aldehyde Reductase; Animals; Caco-2 Cells; Catalytic Domain; Dogs; Enzyme Inhibitors; Humans; Hypoglycemic Agents; Madin Darby Canine Kidney Cells; Male; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Protein Binding; Rats, Wistar; Structure-Activity Relationship; Thiazolidinediones | 2021 |
Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Caenorhabditis elegans; Disease Models, Animal; Memantine; Mice; Receptors, N-Methyl-D-Aspartate | 2022 |
Effects of drugs on the hepatic microsomal glucose-6-phosphatase system.
Topics: Animals; Glucose-6-Phosphatase; Imipramine; Kinetics; Male; Microsomes, Liver; Rats; Rats, Inbred Strains; Verapamil | 1992 |
[Anticalcium activity of several antidepressive agents].
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Arrhythmias, Cardiac; Benzamides; Brain; Calcium; Calcium Chloride; Carbazoles; Female; Imipramine; Male; Mice; Moclobemide; Oxazines; Rats; Verapamil | 1992 |
Teratogenicity testing based on the interaction with a mutant allele.
Topics: Abnormalities, Drug-Induced; Alleles; Animals; Anti-Bacterial Agents; Cyclophosphamide; Female; Fetus; Imipramine; Male; Mutagenicity Tests; Rats; Rats, Inbred Lew; Verapamil | 1992 |
Rapid desensitization of central beta-adrenoceptors in rat after subacute treatment with imipramine and calcium entry blockers.
Topics: 1-Propanol; Animals; Calcium Channel Blockers; Clonidine; Diltiazem; DOM 2,5-Dimethoxy-4-Methylamphetamine; Drinking Behavior; Fenclonine; Imipramine; Isoproterenol; Ketanserin; Nicardipine; Nifedipine; Oxidopamine; Rats; Receptors, Adrenergic, beta; Verapamil | 1991 |
Protective effects of felodipine and verapamil against imipramine-induced lethal cardiac conduction disturbances in the anaesthetized rat.
Topics: Animals; Dose-Response Relationship, Drug; Felodipine; Heart Conduction System; Hemodynamics; Imipramine; Male; Rats; Rats, Inbred WKY; Verapamil | 1991 |
Inhibitory action of phospholipid-interacting drugs on transcription initiation in a nuclear extract of Ehrlich ascites tumor cells.
Topics: Adenoviruses, Human; Animals; Carcinoma, Ehrlich Tumor; Cell Nucleus; Chlorpromazine; HeLa Cells; Humans; Imipramine; Kinetics; Mice; Phospholipases A; Phospholipases A2; Phospholipids; Promoter Regions, Genetic; RNA Polymerase II; Tetracaine; Transcription Factors; Transcription, Genetic; Verapamil | 1991 |
Long-term verapamil treatment increases [3H]imipramine binding in human platelets.
Topics: Blood Platelets; Carrier Proteins; Cell Membrane; Female; Heart Diseases; Humans; Imipramine; Male; Middle Aged; Receptors, Drug; Receptors, Neurotransmitter; Serotonin; Up-Regulation; Verapamil | 1990 |
[Effect of substances modifying calcium movement on the contractility of cultured cardiac cells].
Topics: Animals; Caffeine; Calcium Channel Blockers; Cells, Cultured; Diltiazem; Histamine; Imipramine; Ion Channels; Isoproterenol; Myocardial Contraction; Nifedipine; Phenylephrine; Rats; Verapamil | 1985 |
Pituitary thyrotropin-releasing hormone receptors: local anesthetic effects on binding and responses.
Topics: Anesthetics, Local; Animals; Benzocaine; Chlordiazepoxide; Chlorpromazine; Dibucaine; Hydrogen-Ion Concentration; Imipramine; Lidocaine; Pituitary Gland; Procaine; Prolactin; Propranolol; Rats; Receptors, Neurotransmitter; Receptors, Thyrotropin-Releasing Hormone; Tetracaine; Thyrotropin-Releasing Hormone; Trifluoperazine; Verapamil | 1989 |
Serotonin uptake and configurational change of bovine pulmonary artery smooth muscle cells in culture.
Topics: Animals; Cattle; Cell Division; Cells, Cultured; Hypoxia; Imipramine; Microscopy, Phase-Contrast; Muscle, Smooth, Vascular; Pulmonary Artery; Serotonin; Temperature; Verapamil | 1989 |
Tricyclic antidepressants and calcium channel blockers: interactions at the (-)-desmethoxyverapamil binding site and the serotonin transporter.
Topics: Animals; Antidepressive Agents, Tricyclic; Calcium Channel Blockers; Calcium Channels; Imipramine; In Vitro Techniques; Kinetics; Male; Nitrendipine; Rats; Receptors, Nicotinic; Receptors, Serotonin; Serotonin; Verapamil | 1988 |
Effect of nifedipine on the shuttlebox escape deficit induced by inescapable shock in the rat.
Topics: Animals; Binding Sites; Brain; Depression; Electroshock; Escape Reaction; Imipramine; Kinetics; Male; Nifedipine; Nitrendipine; Rats; Rats, Inbred Strains; Verapamil | 1988 |
Perturbation of in vitro drug resistance in human lymphatic neoplasms by combinations of putative inhibitors of protein kinase C.
Topics: Cell Survival; Chlorpromazine; Drug Resistance; Drug Synergism; Haloperidol; Humans; Imipramine; In Vitro Techniques; Leukemia; Leukemia, Lymphoid; Lidocaine; Protein Kinase C; Tamoxifen; Tumor Cells, Cultured; Verapamil | 1987 |
Verapamil in the treatment of recurrent unipolar depression.
Topics: Adult; Calcium; Depressive Disorder; Drug Therapy, Combination; Female; Humans; Imipramine; Lithium; Recurrence; Verapamil | 1987 |
[Cardiovascular complications of tricyclic anti-depressants. Apropos of a case of acute poisoning].
Topics: Adult; Arrhythmias, Cardiac; Bundle-Branch Block; Diazepam; Digitalis Glycosides; Electrocardiography; Female; Furosemide; Humans; Imipramine; Poisoning; Respiration; Seizures; Tachycardia; Verapamil | 1973 |
Some further observations on the stimulation by high external potassium of the sodium efflux in barnacle muscle fibers.
Topics: Animals; Chelating Agents; Fluorides; Imipramine; Muscles; Phenothiazines; Phenytoin; Potassium; Purine Nucleotides; Sodium; Stimulation, Chemical; Thoracica; Verapamil | 1982 |
Effects of imipramine on frequency-force relationship in isolated right atrial muscle of the dog.
Topics: Animals; Calcium; Dogs; Female; Heart Rate; Imipramine; In Vitro Techniques; Male; Myocardial Contraction; Verapamil | 1981 |
Inhibitory action of chlorpromazine, dibucaine, and other phospholipid-interacting drugs on calcium-activated, phospholipid-dependent protein kinase.
Topics: Animals; Brain; Calcium; Chlorpromazine; Cytosol; Dibucaine; Enzyme Activation; Imipramine; Kinetics; Phentolamine; Phospholipids; Protein Kinases; Rats; Tetracaine; Verapamil | 1980 |
[Ca(2+)-channel blockers and binding of tricyclic antidepressive agents].
Topics: Animals; Antidepressive Agents, Tricyclic; Blood Platelets; Calcium Channel Blockers; Cattle; Cell Membrane; Desipramine; Gallopamil; Humans; Imipramine; In Vitro Techniques; Lymphocytes; Phosphatidylserines; Synaptic Membranes; Verapamil | 1995 |
Na-dependent regulation of intracellular free magnesium concentration in isolated rat ventricular myocytes.
Topics: Animals; Antiporters; Heart Ventricles; Homeostasis; Imipramine; In Vitro Techniques; Ion Channels; Magnesium; Male; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sodium; Statistics as Topic; Strophanthidin; Verapamil | 1996 |
A Na+/Ca2+ exchanger inhibitor, KB-R7943, caused negative inotropic responses and negative followed by positive chronotropic responses in isolated, blood-perfused dog heart preparations.
Topics: Animals; Atropine; Depression, Chemical; Dogs; Dose-Response Relationship, Drug; Heart Rate; Hexamethonium; Imipramine; Isoproterenol; Myocardial Contraction; Ouabain; Perfusion; Propranolol; Sodium-Calcium Exchanger; Tetrodotoxin; Thiourea; Verapamil | 2000 |
Rates of metabolism of chlorzoxazone, dextromethorphan, 7-ethoxycoumarin, imipramine, quinidine, testosterone and verapamil by fresh and cryopreserved rat liver slices, and some comparisons with microsomes.
Topics: Animals; Antidepressive Agents; Antimalarials; Antitussive Agents; Calcium Channel Blockers; Cell Survival; Chlorzoxazone; Coloring Agents; Coumarins; Cryopreservation; Cytochrome P-450 Enzyme System; Dextromethorphan; Imipramine; In Vitro Techniques; Liver; Male; Microsomes, Liver; Muscle Relaxants, Central; Oxazines; Pharmaceutical Preparations; Pharmacokinetics; Quinidine; Rats; Rats, Sprague-Dawley; Subcellular Fractions; Testosterone; Verapamil; Xanthenes | 2003 |
Blockade of calcium entry in smooth muscle cells by the antidepressant imipramine.
Topics: Animals; Antidepressive Agents; Aorta; Calcium; Calcium Channel Blockers; Calcium Channels; Colon; Drug Combinations; Female; Imipramine; Mianserin; Muscle Contraction; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Phenylephrine; Potassium Chloride; Rats; Rats, Wistar; Rubidium; Sertraline; Verapamil | 2004 |
Verapamil in treatment resistant depression: a role for the P-glycoprotein transporter?
Topics: Animals; Antidepressive Agents, Tricyclic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain; Calcium Channel Blockers; Chromatography, High Pressure Liquid; Imipramine; Male; Rats; Rats, Sprague-Dawley; Tissue Distribution; Verapamil | 2009 |
Development of a novel high-throughput analytical methodology, multiple injection method, for quantitative analysis in drug metabolism and pharmacokinetic studies using liquid chromatography with tandem mass spectrometry.
Topics: Animals; Chromatography, High Pressure Liquid; Imipramine; Male; Ondansetron; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Risperidone; Tandem Mass Spectrometry; Terfenadine; Validation Studies as Topic; Verapamil | 2011 |
Exploration of a new concept for automated dried blood spot analysis using flow-through desorption and online SPE-MS/MS.
Topics: Automation; Chromatography, High Pressure Liquid; Dried Blood Spot Testing; Humans; Imipramine; Solid Phase Extraction; Tandem Mass Spectrometry; Verapamil | 2011 |
Pharmacophore modeling for hERG channel facilitation.
Topics: Animals; Atenolol; Chlorpheniramine; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluoxetine; Haloperidol; Humans; Hydrophobic and Hydrophilic Interactions; Imipramine; Metoprolol; Nortriptyline; Potassium Channel Blockers; Promethazine; Propranolol; Quantitative Structure-Activity Relationship; Sotalol; Terfenadine; Verapamil; Xenopus laevis | 2012 |
Inhibition of P-glycoprotein enhances transport of imipramine across the blood-brain barrier: microdialysis studies in conscious freely moving rats.
Topics: Animals; Antidepressive Agents, Tricyclic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biotransformation; Blood-Brain Barrier; Cyclosporine; Desipramine; Drug Interactions; Extracellular Fluid; Half-Life; Imipramine; Injections, Intravenous; Male; Metabolic Clearance Rate; Microdialysis; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Tissue Distribution; Verapamil | 2012 |
The liver partition coefficient-corrected inhibitory quotient and the pharmacokinetic-pharmacodynamic relationship of directly acting anti-hepatitis C virus agents in humans.
Topics: Animals; Antiviral Agents; Cells, Cultured; Digoxin; Doxorubicin; Hepacivirus; Hepatocytes; Humans; Imipramine; Liver; Male; Mice; Quinidine; Rats; Rats, Sprague-Dawley; Verapamil | 2012 |
Chromatographic studies of drug interactions with alpha
Topics: Chlorpromazine; Chromatography, Affinity; Humans; Imipramine; Orosomucoid; Pharmaceutical Preparations; Propranolol; Protein Binding; Verapamil | 2017 |
Irinotecan Alters the Disposition of Morphine Via Inhibition of Organic Cation Transporter 1 (OCT1) and 2 (OCT2).
Topics: Amitriptyline; Animals; Drug Interactions; Fluoxetine; HEK293 Cells; Humans; Imipramine; Irinotecan; Mice, Inbred C57BL; Morphine; Narcotics; Ondansetron; Organic Cation Transport Proteins; Organic Cation Transporter 1; Organic Cation Transporter 2; Tissue Distribution; Verapamil | 2018 |
An Experimental and Theoretical Study of Laser Postionization of Femtosecond-Laser-Desorbed Drug Molecules.
Topics: Carbamazepine; Ciprofloxacin; Imipramine; Ions; Kinetics; Lasers; Models, Molecular; Molecular Conformation; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Verapamil | 2020 |